SEBI Secretarial Compliance Report for the year ended 31.03.2026
Board meeting outcome
1. Audited financial results for the quarter and year ended 31.03.2026 2. Audit Report for the quarter and year ended 31.03.2026 3. Any other business with the permission of the Chair.
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Vista Pharmaceuticals Ltd 2 CIN NO. L24239TG1991PLC012264 3 Report filed for FY 2025-2026 Details of the Current block (all figures in Rs crore): 4 2 – year block period (Specify financial years)* 2025-26, 2026-27 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T – 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T – 1) which was carried forward to FY(T)}(f) = (b) – [(c) – (e)]{ If the calculated value is zero or negative, write “nil”}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 – year Block period (Specify financial years)2024-25, 2025-26 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) – (e)}#0.00 Name of the Company Secretary :-Barka JainDesignation :-Company Secretary compliance Officer Name of the Chief Financial Officer :- Suneel pachipala Designation : -CFO Date: 29/04/2026
Compliance - certificate under Reg. 74(5) of SEBI (DP) Regulations 2018
Closure of Trading Window
Un audited Financial Results for the quarter ended 31.12.2025
Results for the quarter ended 31.12.2025
The Board Meeting to be held on 23/02/2026 has been revised to 13/02/2026
1. Unaudited financial results for the quarter and nine months ended 31.12.2025. 2. Limited Review Report quarter and nine months 31.12.2025. 3. Any other business with the permission of the Chair.
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 1.98 | 3.47 | 1.70 | 3.13 | 1.80 | 2.49 | 2.56 | 3.23 | 1.52 | 1.46 | 2.42 | 0.00 |
| YOY Revenue Growth % | - | - | - | 212.1% | -9.39% | -28.1% | 49.9% | 3.11% | -15.39% | -41.37% | -5.35% | -100% |
| Other Income | 0.13 | 0.08 | 0.02 | 0.10 | 0.07 | 0.01 | 0.12 | 0.24 | 0.00 | 0.19 | 0.09 | 0.03 |
| Total Income | 2.11 | 3.55 | 1.73 | 3.23 | 1.87 | 2.50 | 2.68 | 3.47 | 1.52 | 1.65 | 2.51 | 0.03 |
| Total Expenses + | 3.40 | 5.14 | 3.93 | 3.33 | 3.04 | 3.75 | 4.48 | 4.53 | 3.00 | 5.28 | 5.79 | 7.80 |
| Cost of Materials Consumed | 2.06 | 3.11 | 2.21 | 1.49 | 1.60 | 1.55 | 2.05 | 2.69 | 1.50 | 1.46 | 2.26 | 0.00 |
| Employee Benefit Expense | 0.42 | 0.45 | 0.45 | 0.48 | 0.45 | 0.48 | 0.52 | 0.56 | 0.54 | 0.57 | 0.59 | 0.50 |
| Other Expenses | 0.52 | 0.99 | 0.78 | 0.89 | 0.52 | 1.29 | 1.06 | 0.89 | 0.59 | 2.87 | 2.57 | 6.56 |
| Operating Profit | -1.42 | -1.67 | -2.23 | -0.20 | -1.24 | -1.26 | -1.93 | -1.30 | -1.48 | -3.81 | -3.37 | -7.80 |
| OPM % | -71.7% | -48.1% | -130.6% | -6.3% | -69.2% | -50.5% | -75.4% | -40.3% | -97.5% | -260.8% | -139.4% | 0% |
| Profit Before Tax + | -1.29 | -1.59 | -2.20 | -0.10 | -1.17 | -1.25 | -1.80 | -1.06 | -1.48 | -3.62 | -3.28 | -7.77 |
| Tax Expense | -0.33 | 0.43 | -0.57 | -0.19 | -0.31 | -0.28 | -0.48 | 0.43 | -0.19 | -1.03 | -0.96 | -1.91 |
| Tax % | - | - | - | - | - | - | - | - | - | - | - | - |
| Profit After Tax | -0.95 | -2.02 | -1.63 | 0.09 | -0.86 | -0.97 | -1.32 | -1.50 | -1.29 | -2.59 | -2.32 | -5.86 |
| EPS (Basic) | -0.46 | -0.46 | -0.33 | 0.02 | -0.15 | 0.00 | -0.07 | -0.26 | -0.22 | -0.42 | -0.41 | -0.91 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| Revenue from Operations | 5.40 | 10.07 | 10.29 | 1.00 | 0.39 | 1.27 |
| YOY Revenue Growth % | -46.4% | -2.07% | 924.99% | 154.36% | -68.84% | - |
| Other Income | 0.32 | 0.44 | 0.33 | 0.29 | 0.17 | 0.32 |
| Total Income | 5.71 | 10.52 | 10.62 | 1.29 | 0.56 | 1.58 |
| Total Expenses + | 21.87 | 15.81 | 15.80 | 6.01 | 3.12 | 5.27 |
| Cost of Materials Consumed | 5.22 | 7.90 | 8.88 | 1.23 | 0.37 | 0.73 |
| Employee Benefit Expense | 2.20 | 2.00 | 1.79 | 0.58 | 0.57 | 1.15 |
| Other Expenses | 12.59 | 3.75 | 3.17 | 1.41 | 0.66 | 1.11 |
| Operating Profit | -16.47 | -5.73 | -5.51 | -5.01 | -2.73 | -4.01 |
| OPM % | -305% | -56.9% | -53.6% | -498.9% | -691% | -316.4% |
| Profit Before Exceptional | -16.15 | -5.29 | -5.18 | -4.72 | -2.56 | -3.69 |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit Before Tax + | -16.15 | -5.29 | -5.18 | -4.72 | -2.56 | -3.69 |
| Tax Expense | -4.09 | -0.64 | -0.67 | 1.09 | -1.73 | -1.80 |
| Tax % | - | - | - | - | - | - |
| Profit After Tax | -12.06 | -4.65 | -4.51 | -5.82 | -0.83 | -1.89 |
| EPS (Basic) | -1.96 | -0.79 | -1.03 | -1.58 | -0.24 | -0.63 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Non-Current Assets + | 39.72 | 45.53 | 34.58 | 35.62 | 40.24 | 35.62 |
| Property, Plant & Equipment | 8.71 | 9.15 | 9.77 | 10.19 | 9.78 | 10.38 |
| Capital Work in Progress | 10.61 | 10.14 | 9.82 | 9.33 | 9.08 | 9.08 |
| Non-Current Investments | 0.04 | 0.05 | 0.02 | 0.02 | 0.03 | 0.04 |
| Goodwill | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Intangible Assets | 0.00 | 9.55 | 9.55 | 8.60 | 9.55 | 9.55 |
| Current Assets + | 15.36 | 14.76 | 23.40 | 20.92 | 15.34 | 15.24 |
| Inventories | 11.01 | 8.22 | 6.79 | 9.28 | 9.33 | 9.68 |
| Trade Receivables | 0.32 | 3.39 | 14.28 | 6.27 | 2.57 | 2.17 |
| Cash and Cash Equivalents | 0.11 | 0.01 | 0.09 | 0.00 | 0.07 | 0.14 |
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| LIABILITIES & EQUITY | ||||||
| Total Equity | 36.44 | 45.42 | 40.46 | 36.54 | 35.45 | 32.85 |
| Equity Share Capital | 12.31 | 12.31 | 9.43 | 7.36 | 7.36 | 7.36 |
| Other Equity | 24.13 | 33.11 | 31.03 | 29.18 | 28.09 | 25.49 |
| Non-Current Liabilities | 2.00 | 2.50 | 3.02 | 5.24 | 16.02 | 8.76 |
| Current Liabilities | 16.65 | 12.37 | 14.49 | 14.76 | 4.12 | 9.25 |
| Total Liabilities | 18.64 | 14.87 | 17.52 | 19.99 | 20.14 | 18.01 |
| Particulars | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
| Cash from Operating Activities | -4.40 | -6.98 | -4.92 | -1.72 | -1.13 | -6.75 |
| Cash from Investing Activities | -0.78 | -0.44 | -0.79 | -1.27 | -0.01 | -0.30 |
| Cash from Financing Activities | 4.56 | 8.06 | 5.59 | 2.99 | 1.07 | 6.96 |
| Net Increase/Decrease in Cash | -0.63 | 0.64 | -0.11 | 0.00 | -0.07 | -0.09 |